Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its lead drug candidate, Lucid-MS, into a Phase 2 clinical trial for multiple sclerosis (MS), according to a recent podcast interview with co-founder and executive co-chair Anthony Durkacz. The trial will mark the first time Lucid-MS is tested in MS patients, a critical step for a therapy that targets myelin, the protective sheath around nerve fibers that is damaged in MS. Preclinical models have shown the compound can prevent and reverse myelin degradation, the underlying mechanism of the disease. This development matters because current MS treatments primarily manage symptoms and slow progression but do not repair myelin. If Lucid-MS proves safe and effective in humans, it could represent a new class of therapy for a disease affecting millions worldwide.
In the same interview on The BioMedWire Podcast, Durkacz discussed unbuzzd(TM), a product designed to accelerate alcohol metabolism. Quantum BioPharma invented unbuzzd(TM) and spun out its over-the-counter version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake as of March 31, 2026. The agreement also includes a 7% royalty on sales until payments to Quantum reach $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. This royalty stream could provide substantial non-dilutive funding for Quantum’s research pipeline, while the product itself addresses a growing consumer interest in alcohol misuse and recovery solutions.
For investors, the dual catalysts of a Phase 2 trial readout and a commercial royalty stream may offer multiple avenues for value creation. The MS market is large and underserved by restorative therapies, while the alcohol misuse space is expanding rapidly with few FDA-approved options. Quantum’s approach—developing a novel chemical entity for a neurodegenerative condition while monetizing a consumer health product—is unusual but potentially synergistic. The company’s focus on challenging neurodegenerative and metabolic disorders aligns with broader industry trends toward disease-modifying treatments and preventive health.
BioMedWire, a specialized communications platform for the biotechnology, biomedical sciences, and life sciences sectors, featured the interview. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions, syndication to over 5,000 outlets, press release enhancement, social media distribution, and corporate communications solutions. The full press release can be viewed at https://ibn.fm/ovRTM. For more information about Quantum BioPharma, visit Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM). Additional details are available at BioMedWire and InvestorWire. Please review the full terms of use and disclaimers on the BioMedWire website at https://www.BioMedWire.com/Disclaimer.
